Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xcopri | cenobamate | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
| Fycompa | Perampanel | Epilepsy, partial onset seizures | List with criteria/condition | Complete | ||
| Vimpat | Lacosamide | Epilepsy, partial onset seizures | List with clinical criteria and/or conditions | Complete | ||
| pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nucala | mepolizumab | Eosinophilic granulomatosis with polyangiitis | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| N/A | mepolizumab | Eosinophilic Granulomatosis with Polyangiitis | Active | |||
| Jorveza | budesonide | Eosinophilic esophagitis, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
| Jemperli | dostarlimab | Endometrial cancer | Do not reimburse | Complete | ||
| Jemperli | dostarlimab | Endometrial cancer | Active | |||
| Isturisa | osilodrostat | Endogenous Cushing’s syndrome | Suspended |
Last Updated : May 17, 2024